Sep 2026 (Q3 FY26) — Oct 13, 2026
Johnson & Johnson Q3 FY26 — Strong Innovative Medicine Performance Drives Sales Beat and Raised Full-Year Guidance
Read the full callJohnson & Johnson (JNJ) earnings
- Jun 2026
- Sep 2026 (Q3 FY26)
- Dec 2025
Johnson & Johnson earnings: last reported Tue, 13 Oct 2026, for the quarter ended Sep 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 25,310 | +6.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 5,534 | −0.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Guidance
What management said, and what became of it
27 of 29 judged targets kept · 36 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Nipocalimab approval in generalized myasthenia gravis | approval in 2025 | Sep 2024 | We continue to see strong uptake of IMAAVY in generalized myasthenia gravis and recently received FDA priority review status in warm autoimmune hemolytic anemia | Achieved |
| Anti-tau antibody Phase II data presentation | data in-house in 2025 and presented at a medical congress in 1H 2026 | Sep 2025 | We also have important data readouts across our innovative medicine pipeline, including Tech Valley in combination with TECVAYLI ... Pasritamig, a first-in-class bispecific antibody ... and J&J-6143 | Ghosted |
| Full-year adjusted operational EPS | $11.28 to $11.48 | Dec 2025 | increase our adjusted operational earnings per share range to $11.50 to $11.65, which equates to an increase of $0.18 at the midpoint | Revised Up |
2 of JOHNSON & JOHNSON's 65 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 62 more targets are in the full ledger.
Claimed
- Worldwide operational sales grew 6%, exceeding analyst consensus.
- Innovative Medicine operational sales grew 7.9%, with 8 brands achieving double-digit growth.
- Oncology business grew approximately 17%, driven by multiple myeloma portfolio and RYBREVANT.
- TREMFYA delivered exceptional sales growth of 68%, becoming brand share leader in ulcerative colitis and Crohn's disease in the U.S.
- Full-year operational sales guidance raised to $100.7 billion at the midpoint, on track to exceed $100 billion annual revenue for the first time.
Qualified
- MedTech operational sales grew only 2.5%, falling short of expectations, particularly in cardiovascular and surgery outside the U.S.
- Abiomed sales declined 1.5% due to lower patient volume, attributed to a study outside the U.S. focused on high-risk PCI.
- STELARA sales declined 54% due to competitive pressures from biosimilars.
- Net earnings were $210 million, significantly down from $2.12 billion a year ago, impacted by a $5.5 billion talc litigation resolution and $1 billion Firefly Bio acquisition.
- Adjusted diluted EPS decreased 7.5% to $2.59, impacted by Firefly Bio acquisition and Sale Biomedicines collaboration expenses.
Price
$253.79 −0.69% · −$1.77
Performance +31.3% 1Y
1Y: $193.22 on 17 Oct 2025 → $253.79. High $278.43 (3 Sept 2026), low $186 (5 Nov 2025).
- Previous close
- $255.56
- 52-week range
- $186 – $278.43
- One year
- +31.01%
Overview
- Symbol
- JNJ
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
27 of 29 judged targets kept · 36 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Nipocalimab approval in generalized myasthenia gravis | approval in 2025 | Sep 2024 | We continue to see strong uptake of IMAAVY in generalized myasthenia gravis and recently received FDA priority review status in warm autoimmune hemolytic anemia | Achieved |
| Anti-tau antibody Phase II data presentation | data in-house in 2025 and presented at a medical congress in 1H 2026 | Sep 2025 | We also have important data readouts across our innovative medicine pipeline, including Tech Valley in combination with TECVAYLI ... Pasritamig, a first-in-class bispecific antibody ... and J&J-6143 | Ghosted |
| Full-year adjusted operational EPS | $11.28 to $11.48 | Dec 2025 | increase our adjusted operational earnings per share range to $11.50 to $11.65, which equates to an increase of $0.18 at the midpoint | Revised Up |
Claimed
- Worldwide operational sales grew 6%, exceeding analyst consensus.
- Innovative Medicine operational sales grew 7.9%, with 8 brands achieving double-digit growth.
- Oncology business grew approximately 17%, driven by multiple myeloma portfolio and RYBREVANT.
- TREMFYA delivered exceptional sales growth of 68%, becoming brand share leader in ulcerative colitis and Crohn's disease in the U.S.
- Full-year operational sales guidance raised to $100.7 billion at the midpoint, on track to exceed $100 billion annual revenue for the first time.
Qualified
- MedTech operational sales grew only 2.5%, falling short of expectations, particularly in cardiovascular and surgery outside the U.S.
- Abiomed sales declined 1.5% due to lower patient volume, attributed to a study outside the U.S. focused on high-risk PCI.
- STELARA sales declined 54% due to competitive pressures from biosimilars.
- Net earnings were $210 million, significantly down from $2.12 billion a year ago, impacted by a $5.5 billion talc litigation resolution and $1 billion Firefly Bio acquisition.
- Adjusted diluted EPS decreased 7.5% to $2.59, impacted by Firefly Bio acquisition and Sale Biomedicines collaboration expenses.
The full ledger
Open JOHNSON & JOHNSON’s full ledger
A free account opens 5 company ledgers a month. All 65 tracked commitments, with each call’s wording and source.
Call summaries
Jun 2026 (Q2 FY26) — Jul 15, 2026
Johnson & Johnson Q2 FY26 — Strong Growth Driven by New Launches and Raised Full-Year Guidance
Read the full callMar 2026 (Q1 FY26) — Apr 14, 2026
Johnson & Johnson Q1 FY26 — Strong Start with Raised Guidance and Pipeline Momentum
Read the full callNews
Latest news
From the news desk, item by item, hours after each call.
Every analysed call
Johnson & Johnson earnings calls (JNJ)
Financials
What the filings say
Net profit, year on year: 0% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 22,471 | 22,520 | 21,893 | 23,743 | 23,993 | 24,564 | 24,062 | 25,310 |
| Interest | 193 | 137 | 204 | 308 | 245 | 214 | 272 | 281 |
| Profit before tax | 3,338 | 3,887 | 13,631 | 6,491 | 7,493 | 4,966 | 5,990 | 6,747 |
| Tax rate | 19.3% | 11.7% | 19.3% | 14.7% | 31.2% | −3.0% | 12.6% | 18.0% |
| Net profit | 2,694 | 3,431 | 10,999 | 5,537 | 5,152 | 5,116 | 5,235 | 5,534 |
| EPS ($ per share) | 1.12 | — | 4.57 | 2.30 | 2.14 | — | 2.17 | 2.30 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 |
| Reserves | 106,216 | 110,659 | 113,890 | 123,060 | 128,345 | 153,843 | 155,791 | 168,978 |
| Total liabilities | 93,202 | 98,257 | 111,616 | 107,995 | 110,574 | 98,784 | 108,614 | 117,666 |
| Fixed assets | 17,035 | 17,658 | 18,766 | 18,962 | 17,982 | 19,898 | 20,518 | 23,169 |
| Investments | 1,580 | 1,982 | 11,200 | 17,121 | 9,392 | 1,068 | 417 | 393 |
| Total assets | 152,954 | 157,728 | 174,894 | 182,018 | 187,378 | 167,558 | 180,104 | 199,210 |
| Line item | Dec 2018 | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 22,201 | 23,416 | 23,536 | 23,410 | 21,194 | 22,791 | 24,266 | 24,530 |
| Cash from investing | -3,167 | -6,194 | -20,825 | -8,683 | -12,371 | 878 | -18,599 | -23,588 |
| Cash from financing | -18,510 | -18,015 | -6,120 | -14,047 | -8,871 | -15,825 | -3,132 | -5,539 |
| Net cash flow | 283 | -802 | -3,320 | 502 | -360 | 7,732 | 2,246 | -4,396 |
| Capital expenditure | -3,670 | -3,498 | -3,347 | -3,652 | -4,009 | -4,543 | -4,424 | -4,832 |
| Free cash flow | 18,531 | 19,918 | 20,189 | 19,758 | 17,185 | 18,248 | 19,842 | 19,698 |
JNJ revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2027 | Q2 FY2027 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | 65% | 64% | 63% | 64% | 65% | 64% | 64% | 65% | +7.8% |
| Med Tech | 35% | 36% | 37% | 36% | 35% | 36% | 36% | 35% | +4.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2027 · share of revenue
- US 57%
- Europe 23% ↑ 1 pt
- Asia Pacific Africa 15% ↓ 1 pt
- Western Hemisphere Excluding US 5%
- UNITEDSTATES Exports <1%
As JNJ cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
142 filings between Nov 26, 2025 and Sep 2, 2026.
Open market
decisions to buy or sellPurchases
$257.7K
1 purchase by 1 insider
Sales
$150.67M
28 sales by 10 insiders
Compensation
not trading decisions- 66
- Option exercise — converted options into shares
- 47
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Duato Joaquin | — | $66.84M | Aug 13, 2026 |
| Wolk Joseph J | — | $21.77M | Feb 17, 2026 |
| Swanson James D. | — | $15.11M | Feb 17, 2026 |
| Schmid Timothy | — | $15.08M | Sep 2, 2026 |
| REED JOHN C | — | $13.11M | Feb 17, 2026 |
| Broadhurst Vanessa | — | $7.30M | Jul 20, 2026 |
| Forminard Elizabeth | — | $4.09M | Aug 6, 2026 |
| Taubert Jennifer L | — | $3.95M | Aug 17, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 11,070 | $1.46M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 11,070 | $3.04M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 22,527 | $6.19M |
| Sep 2, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 22,527 | $3.41M |
| Aug 17, 2026 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Option exercise | 15,000 | $1.74M |
| Aug 17, 2026 | Taubert Jennifer L EVP, WWC. Innovative Medicine | Sale | 15,000 | $3.95M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Sale | 20,976 | $5.50M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Sale | 102,315 | $26.70M |
| Aug 13, 2026 | Duato Joaquin CEO and Chairman of the Board | Option exercise | 123,291 | $14.26M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Sale | 9,344 | $2.41M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Sale | 6,574 | $1.68M |
| Aug 6, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Option exercise | 9,344 | $1.23M |
| Aug 5, 2026 | Duato Joaquin CEO and Chairman of the Board | Sale | 6,523 | $1.69M |
| Aug 5, 2026 | Duato Joaquin CEO and Chairman of the Board | Sale | 41,957 | $10.83M |
| Jul 20, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | 11,925 | $1.57M |
| Jul 20, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | 11,129 | $1.44M |
| Jul 20, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Sale | 23,054 | $5.79M |
| Jun 11, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Sale | 10,000 | $2.41M |
| Jun 11, 2026 | Wengel Kathryn E EVP, Chief TO and Risk Officer | Option exercise | 10,000 | $1.16M |
| May 1, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Tax withheld | 11,002 | $2.53M |
| May 1, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | 25,255 | $0 |
| Feb 27, 2026 | Decker Robert J VP Corporate Controller | Option exercise | 4,075 | $471.4K |
| Feb 27, 2026 | Decker Robert J VP Corporate Controller | Sale | 4,075 | $1.01M |
| Feb 20, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 1,322 | $324.8K |
| Feb 18, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 8,998 | $2.20M |
| Feb 18, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 13,625 | $1.58M |
| Feb 18, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Sale | 13,625 | $3.33M |
| Feb 18, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 8,998 | $1.17M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Sale | 33,386 | $8.10M |
| Feb 17, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | 2,283 | $554.8K |
| Feb 17, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | 29,927 | $7.27M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Sale | 24,961 | $6.06M |
| Feb 17, 2026 | Swanson James D. EVP, CIO | Option exercise | 20,521 | $3.38M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Sale | 12,066 | $2.93M |
| Feb 17, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | 29,927 | $4.67M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Option exercise | 33,386 | $4.40M |
| Feb 17, 2026 | Swanson James D. EVP, CIO | Sale | 20,521 | $4.98M |
| Feb 17, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | 21,721 | $3.43M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Option exercise | 19,241 | $2.23M |
| Feb 17, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Sale | 6,197 | $1.51M |
| Feb 17, 2026 | REED JOHN C EVP, Innovative Medicine, R&D | Sale | 21,721 | $5.28M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Option exercise | 12,066 | $1.56M |
| Feb 17, 2026 | Wolk Joseph J Exec VP, CFO | Sale | 19,241 | $4.68M |
| Feb 15, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Tax withheld | 252 | $61.3K |
| Feb 15, 2026 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | 492 | $0 |
| Feb 15, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Tax withheld | 492 | $119.8K |
| Feb 15, 2026 | Forminard Elizabeth EVP, Chief Legal Officer | Option exercise | 1,063 | $0 |
| Feb 15, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Tax withheld | 448 | $109.1K |
| Feb 15, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Option exercise | 1,026 | $0 |
| Feb 15, 2026 | Schmid Timothy EVP, WW Chair, MedTech | Tax withheld | 15 | $3.7K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for JOHNSON & JOHNSON
Free account. Everything above stays public.
Write why you follow JOHNSON & JOHNSON and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other companies in Health Care
Nearest to Johnson & Johnson by market cap among the sector's top 20 companies at Q2 2026.